BlackThorn Therapeutics racks up $76 mln Series B

San Francisco-based BlackThorn Therapeutics, a neurobehavioral health company, has secured $76 million in Series B financing. The investors included Polaris Partners, Premier Partners, Scripps Research, Vertex Ventures HC, Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, Biomatics Capital, GV, Johnson & Johnson Innovation – JJDC, Inc. and Mercury Fund. In connection with the financing, Brian Chee, a managing partner at Polaris Partners, Lori Hu, a managing director at Vertex Ventures HC and Julie Sunderland, a managing director at Biomatics Capital, joined BlackThorn’s board as directors.

Source: Press Release